Logo image of GBIO

GENERATION BIO CO (GBIO) Stock Fundamental Analysis

NASDAQ:GBIO - Nasdaq - US37148K1007 - Common Stock - Currency: USD

0.4395  0 (-0.11%)

Fundamental Rating

3

GBIO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. GBIO has a great financial health rating, but its profitability evaluates not so good. GBIO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GBIO has reported negative net income.
In the past year GBIO has reported a negative cash flow from operations.
In the past 5 years GBIO always reported negative net income.
In the past 5 years GBIO always reported negative operating cash flow.
GBIO Yearly Net Income VS EBIT VS OCF VS FCFGBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -56.95%, GBIO perfoms like the industry average, outperforming 42.05% of the companies in the same industry.
GBIO's Return On Equity of -152.74% is on the low side compared to the rest of the industry. GBIO is outperformed by 64.31% of its industry peers.
Industry RankSector Rank
ROA -56.95%
ROE -152.74%
ROIC N/A
ROA(3y)-42.35%
ROA(5y)-35.88%
ROE(3y)-87.81%
ROE(5y)-64.94%
ROIC(3y)N/A
ROIC(5y)N/A
GBIO Yearly ROA, ROE, ROICGBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

GBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GBIO Yearly Profit, Operating, Gross MarginsGBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

7

2. Health

2.1 Basic Checks

GBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GBIO has more shares outstanding
Compared to 5 years ago, GBIO has more shares outstanding
There is no outstanding debt for GBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GBIO Yearly Shares OutstandingGBIO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
GBIO Yearly Total Debt VS Total AssetsGBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -4.36, we must say that GBIO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.36, GBIO is in line with its industry, outperforming 42.23% of the companies in the same industry.
There is no outstanding debt for GBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.36
ROIC/WACCN/A
WACC9.92%
GBIO Yearly LT Debt VS Equity VS FCFGBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.50 indicates that GBIO has no problem at all paying its short term obligations.
GBIO has a better Current ratio (5.50) than 60.25% of its industry peers.
A Quick Ratio of 5.50 indicates that GBIO has no problem at all paying its short term obligations.
With a decent Quick ratio value of 5.50, GBIO is doing good in the industry, outperforming 60.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.5
Quick Ratio 5.5
GBIO Yearly Current Assets VS Current LiabilitesGBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for GBIO have decreased by -1.02% in the last year.
GBIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 236.70%.
EPS 1Y (TTM)-1.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.62%
Revenue 1Y (TTM)236.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%45.52%

3.2 Future

GBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.46% yearly.
GBIO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.31% yearly.
EPS Next Y41.5%
EPS Next 2Y21.85%
EPS Next 3Y14.77%
EPS Next 5Y10.46%
Revenue Next Year-62.78%
Revenue Next 2Y-35.75%
Revenue Next 3Y-24.66%
Revenue Next 5Y11.31%

3.3 Evolution

GBIO Yearly Revenue VS EstimatesGBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
GBIO Yearly EPS VS EstimatesGBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GBIO Price Earnings VS Forward Price EarningsGBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GBIO Per share dataGBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

GBIO's earnings are expected to grow with 14.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.85%
EPS Next 3Y14.77%

More info and screens

0

5. Dividend

5.1 Amount

GBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENERATION BIO CO

NASDAQ:GBIO (5/2/2025, 1:13:03 PM)

0.4395

0 (-0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners81.62%
Inst Owner Change0.15%
Ins Owners2.79%
Ins Owner Change1.15%
Market Cap29.45M
Analysts80
Price Target6.89 (1467.69%)
Short Float %2.93%
Short Ratio3.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.06%
Min EPS beat(2)-4.08%
Max EPS beat(2)20.2%
EPS beat(4)1
Avg EPS beat(4)-40.52%
Min EPS beat(4)-169.03%
Max EPS beat(4)20.2%
EPS beat(8)3
Avg EPS beat(8)-20.76%
EPS beat(12)5
Avg EPS beat(12)-12.87%
EPS beat(16)7
Avg EPS beat(16)-10.1%
Revenue beat(2)2
Avg Revenue beat(2)178.84%
Min Revenue beat(2)64.24%
Max Revenue beat(2)293.44%
Revenue beat(4)4
Avg Revenue beat(4)142.41%
Min Revenue beat(4)64.24%
Max Revenue beat(4)293.44%
Revenue beat(8)6
Avg Revenue beat(8)89.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.57%
PT rev (3m)-3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)14.13%
Revenue NY rev (1m)-5.06%
Revenue NY rev (3m)-5.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.48
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-1.98
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-1.36
FCFYN/A
OCF(TTM)-1.32
OCFYN/A
SpS0.3
BVpS1.29
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.95%
ROE -152.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.35%
ROA(5y)-35.88%
ROE(3y)-87.81%
ROE(5y)-64.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.69%
Cap/Sales 12.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.5
Quick Ratio 5.5
Altman-Z -4.36
F-Score4
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)120.26%
Cap/Depr(5y)130.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.62%
EPS Next Y41.5%
EPS Next 2Y21.85%
EPS Next 3Y14.77%
EPS Next 5Y10.46%
Revenue 1Y (TTM)236.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%45.52%
Revenue Next Year-62.78%
Revenue Next 2Y-35.75%
Revenue Next 3Y-24.66%
Revenue Next 5Y11.31%
EBIT growth 1Y42.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-51.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-67.91%
OCF growth 3YN/A
OCF growth 5YN/A